Indaptus Therapeutics (NASDAQ: INDP) reported a narrowed net loss for the second quarter of 2026, with earnings per share of $(0.02) significantly beating the analyst consensus estimate of $(1.57) by 98.73%. The biotechnology company’s results reflect a sharp reduction in operational costs following the discontinuation of its primary clinical program, while strengthening its balance sheet through a recent private placement.

For the three months ended June 30, 2026, Indaptus recorded a net loss of approximately $1.8 million, down from $5.2 million in the same quarter of 2025. This represents a 99.78% improvement over the losses of $(9.09) per share from the same period last year. For the first six months of 2026, the net loss stood at approximately $4.3 million, compared with $9.8 million in the prior year period.

Operational Wind-Down and Cost Reduction

The reduction in losses was primarily attributed to lower clinical costs associated with the Decoy20 Phase 1 study and decreased payroll expenses following headcount reductions. Research and development expenses fell 83% to approximately $0.4 million for the quarter, compared with $2.2 million in Q2 2025. For the first half of 2026, R&D expenses totaled approximately $0.9 million, down from $5.0 million in the same period last year.

General and administrative expenses also declined, dropping 37% to approximately $1.4 million for the quarter, compared with $2.3 million in Q2 2025. This decrease was driven by lower payroll costs and changes in public-company costs during the management transition.

Liquidity and Strategic Update

On June 17, 2026, Indaptus completed a private placement, issuing 20,000,000 shares of common stock at $0.60 per share for aggregate gross proceeds of approximately $12.0 million. As of June 30, 2026, the company held approximately $7.6 million in cash and cash equivalents and $4.0 million in short-term investments, totaling $11.6 million in liquid assets. This represents an improvement in liquidity compared to the first quarter end.

The company has discontinued further enrollment in its combination study and has no participants remaining in any ongoing Decoy20 clinical study. Consequently, Indaptus currently has no active clinical development programs. Management is evaluating strategic alternatives for the Decoy20 platform and broader operations, including potential research collaborations, investments, or business combinations.

What the Numbers Show

The financial results highlight a sharp divergence between operational cost reduction and financing activity. While operating expenses dropped significantly due to the cessation of clinical trials, the company’s total assets increased from $9.3 million at year-end 2025 to $12.0 million in June 2026, primarily driven by the $12.0 million equity infusion rather than operational cash generation. Net cash used in operating activities was $8.9 million for the first half of 2026, underscoring that the improved balance sheet position is entirely dependent on external capital raising rather than internal cash flow generation.

Indaptus Therapeutics filed a prospectus with the Securities and Exchange Commission (SEC) related to the resale of up to 18.86 million shares of common stock by selling stockholders. The filing outlines the regulatory framework for the distribution of these shares on the open market. This move follows the company's previous capital raising activities and provides a mechanism for existing shareholders to liquidate holdings.

The prospectus details the specific number of shares available for resale, totaling 18.86 million. It does not indicate a new issuance of stock by the company but rather the resale of existing equity by selling stockholders. The document serves as a formal registration statement required under securities laws to facilitate these transactions.

This development occurs alongside recent financial activities involving the company's equity structure. Previously, Indaptus entered into agreements to sell shares, and this new filing addresses the secondary market implications of those holdings. The prospectus ensures that the resale complies with federal securities regulations.